| Kenneth C Prather, MD | |
|
700 W Grove St, El Dorado, AR 71730-4416 | |
| (870) 863-2000 | |
| Not Available |
| Full Name | Kenneth C Prather |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 43 Years |
| Location | 700 W Grove St, El Dorado, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023086931 | NPI | - | NPPES |
| 54158 | Other | AR | BLUE CROSS |
| 106158001 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | C5928 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ashley County Medical Center | Crossett, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crossett Health Foundation | 9133030117 | 15 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
| Entity Name | Crossett Health Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548252745 PECOS PAC ID: 9133030117 Enrollment ID: O20040311001373 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
| Entity Name | Arkansas Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774630 PECOS PAC ID: 3274681341 Enrollment ID: O20090501000014 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
| Entity Name | Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881967305 PECOS PAC ID: 6103085295 Enrollment ID: O20120308000726 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
| Entity Name | Healogics Specialty Physicians Of Arkansas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538561436 PECOS PAC ID: 9739405408 Enrollment ID: O20150225000284 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kenneth C Prather, MD 5220 Belfort Rd, Atten: Julie Kaye, Jacksonville, FL 32256-6017 Ph: (904) 446-3737 | Kenneth C Prather, MD 700 W Grove St, El Dorado, AR 71730-4416 Ph: (870) 863-2000 |
News Archive
Allogenic hematopoietic stem cell transplantation (HSCT) is a procedure that infuses a donor's healthy blood-forming stem cells into a recipient as part of a potentially curative therapy for cancer.
iMedX Inc., a leading healthcare software and services company, announced today that it has acquired the assets of MedTech Transcriptions Inc., a medical transcription company serving medical clinics in Louisiana for over 15 years. With the acquisition of MedTech, iMedX extends its customer base into Louisiana. MedTech's production and customer service teams will augment iMedX's staff to continue to provide superior services to clients across the United States.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 3 days ago
Dr. James E Seale Jr., M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 701 W Oak St, El Dorado, AR 71730 Phone: 870-863-7154 | |
Dr. Gregory S. Backofen, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 460 W Oak St, El Dorado, AR 71730 Phone: 870-881-4463 |